Results 21 to 30 of about 2,763 (183)
Long-term safety and continued clinical benefit of erenumab 70 mg in Asian patients with chronic migraine: an open-label extension of the phase 3 DRAGON study [PDF]
The Journal of Headache and PainBackground Erenumab is a fully human monoclonal antibody targeting the calcitonin gene-related peptide receptor. Several double‐blind studies have demonstrated the clinical benefits of erenumab in migraine prevention. However, long-term studies on safety
Shengyuan Yu +9 more
doaj +2 more sources
Late-Onset Ocular Myasthenia Gravis-Like Symptoms During Erenumab Therapy for Chronic Migraine: A Case Report. [PDF]
BiologicsChronic migraine (CM) is a disabling neurological disorder for which calcitonin gene-related peptide (CGRP)\u2013targeted monoclonal antibodies, such as erenumab, provide effective prophylaxis.
Qaqish A, Al Anber A, Abdelhafez G.
europepmc +2 more sources
Journal of Comparative Effectiveness ResearchAim: To compare the efficacy of erenumab versus rimegepant as preventive treatment for patients with episodic and chronic migraine using an anchor-based matching-adjusted indirect comparison.
Ronan Mahon +7 more
doaj +2 more sources
Chinese Journal of Contemporary Neurology and Neurosurgery, 2018 Objective To systematically evaluate the clinical efficacy and safety of erenumab in the preventive treatment of migraine in adults. Methods Taking Erenumab or AMG334 AND Migraine as search terms, retrieve in databases such as PubMed, Cochrane Library ...
Yan LIN, Deng CHEN, Da XU, Ling LIU
doaj +2 more sources
Sequential use of OnabotulinumtoxinA and Erenumab in Chronic Migraine: Retrospective Real-World Report on Bidirectional Switching [PDF]
Neurology and TherapyIntroduction In clinical practice, switching between preventive treatments is common in patients with chronic migraine when efficacy is insufficient or tolerability is poor.
Carolin Luisa Hoehne +7 more
doaj +2 more sources
Serum CGRP in migraine patients using erenumab as preventive treatment [PDF]
, 2022 Aim Serum levels of Calcitonin Gene-Related Peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients before and after starting treatment with erenumab were measured to evaluate the association with clinical treatment response.
Lentsch, S.D. +4 more
core +4 more sources
Long-term efficacy and safety of erenumab results from 64 weeks of the LIBERTY study [PDF]
, 2021 ObjectiveTo report the efficacy and safety of erenumab among patients with episodic migraine (EM) whowere unsuccessful on 2 to 4 preventive treatments observed at week 64 of the open-label extension phase (OLEP) of A Study Evaluating the Effectiveness of
Goadsby, P.J. +10 more
core +1 more source
Efficacy and safety of erenumab in migraine prevention
, 2022 The optimal dose of erenumab for patients with migraine remains uncertain. Therefore, we conducted a network meta-analysis to assess the comparative effectiveness of various doses of erenumab for patients with ...
Xing Wang
core +1 more source
Cell Reports, 2020 Summary: Calcitonin-gene-related peptide (CGRP) plays a key role in migraine pathophysiology. Aimovig (erenumab; erenumab-aooe in the United States) is the only US Food and Drug Administration (FDA)-approved monoclonal antibody (mAb) therapy against the ...
Fernando Garces +7 more
doaj +1 more source
The Journal of Headache and Pain, 2022 Abstact Background DRAGON was a phase 3, randomised, double-blind, placebo-controlled study which evaluated the efficacy and safety of erenumab in patients with chronic migraine (CM) from Asia not adequately represented in the global pivotal CM study ...
Shengyuan Yu +13 more
doaj +1 more source